{"success":true,"data":{"pressRelease":{"id":"50617","rtpr_id":"nNFC2GlN0X","ticker":"CBIH","exchange":"OTC","all_tickers":["CBIH"],"title":"CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation","author":"Newsfile Corp","published_at":"2026-06-01T11:00:14.997Z","article_body":"Houston, Texas--(Newsfile Corp. - June 1, 2026) - Cannabis Bioscience\nInternational Holdings, Inc. (OTCID: CBIH), a public company focused on\ncannabinoid biotechnology, applied research, and therapeutic innovation, today\nannounced the completion of a patent-ready melanoma research program focused\non cannabinoid science, oncology biology, aging-related cellular stress, and\nepigenetic regulation.\n\nThe Company views this milestone as part of its broader strategy to build\nresearch-driven intellectual property in cannabinoid biotechnology. CBIH\nbelieves this progress comes at an important moment for cannabinoid medicine,\nas the DEA administrative hearing related to the proposed rescheduling of\nmarijuana from Schedule I to Schedule III, anticipated to begin on June 29,\n2026, may help create a more constructive environment for research, medical\ndevelopment, and institutional participation.\n\n\"CBIH is building its strategy around science, intellectual property,\nformulations, and regulatory discipline,\" said Dante Picazo, Chief Executive\nOfficer of Cannabis Bioscience International Holdings, Inc. \"While much of the\ncannabis sector has been driven by market cycles and short-term expectations,\nour firm is focused on creating a research-driven biotechnology platform in\ncomplex disease areas where inflammation, oxidative stress, immune response,\nmitochondrial function, and gene-expression regulation may overlap. We believe\nthis approach can support future opportunities for licensing, clinical\ncollaboration, manufacturing relationships, strategic partnerships, and\nlong-term shareholder value.\"\n\nEpigenetic regulation refers to biological mechanisms that may influence how\ncells respond to stress without changing the DNA sequence itself. In melanoma\nresearch, these mechanisms may be relevant to tumor behavior, immune response,\ndisease progression, and aging-related cellular stress. \"Our melanoma-related\nprogram reflects CBIH's interest in the relationship between the\nEndocannabinoid System, epigenetic regulation, and complex oncology-related\ndisease mechanisms,\" said Jennifer Salguero, Biologist, PhD in Science,\nUniversity of São Paulo, Brazil, and Chief Patent Officer of CBIH. \"This work\nsupports our broader commitment to disciplined cannabinoid research, patent\ndevelopment, and formulation science.\"\n\nThis initiative forms part of CBIH's portfolio of 25 finalized patent\napplications, including 10 applications already submitted to the USPTO and 15\nadditional applications finalized and ready for submission. The portfolio\ncovers neurological, autoimmune, oncological, metabolic, and other complex\ndisease areas, within a broader body of more than 100 medical formulation\nintellectual property assets.\n\nAs cannabinoid-based medicine continues to evolve, CBIH believes that\nscientific credibility, intellectual property protection, and responsible\nregulatory execution will be essential to building lasting value. The Company\nintends to continue advancing a sustainable competitive advantage from its\nposition as a serious participant in the emerging cannabinoid biotechnology\nsector.\n\nFORWARD-LOOKING STATEMENTS\n\nThis press release may contain forward-looking statements. The words\n\"believe,\" \"expect,\" \"should,\" \"intend,\" \"estimate,\" \"projects,\" variations of\nsuch words and similar expressions identify forward-looking statements, but\ntheir absence does not mean that a statement is not a forward-looking\nstatement. These forward-looking statements are based upon the Company's\ncurrent expectations and are subject to a number of risks, uncertainties, and\nassumptions. The Company undertakes no obligation to update any\nforward-looking statements, whether as a result of new information, future\nevents, or otherwise. Among the important factors that could cause actual\nresults to differ significantly from those expressed or implied by such\nforward-looking statements are risks that are detailed in the Company's\nfilings, which are on file at www.OTCmarkets.com.\n\nFor more information, contact us at:\n\n(214) 733-0868\nir@cbih.net\nDante Picazo\nCEO - CBIH\nWebsite: www.cbih.net\nX: https://x.com/CBIHMD\nInstagram: www.instagram.com/CBIHSTOCK\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/299514","article_body_html":"","raw_payload":{"data":{"id":"nNFC2GlN0X","title":"CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation","author":"Newsfile Corp","ticker":"CBIH","created":"2026-06-01T11:00:14.997Z","tickers":["CBIH"],"exchange":"OTC","article_body":"Houston, Texas--(Newsfile Corp. - June 1, 2026) - Cannabis Bioscience\nInternational Holdings, Inc. (OTCID: CBIH), a public company focused on\ncannabinoid biotechnology, applied research, and therapeutic innovation, today\nannounced the completion of a patent-ready melanoma research program focused\non cannabinoid science, oncology biology, aging-related cellular stress, and\nepigenetic regulation.\n\nThe Company views this milestone as part of its broader strategy to build\nresearch-driven intellectual property in cannabinoid biotechnology. CBIH\nbelieves this progress comes at an important moment for cannabinoid medicine,\nas the DEA administrative hearing related to the proposed rescheduling of\nmarijuana from Schedule I to Schedule III, anticipated to begin on June 29,\n2026, may help create a more constructive environment for research, medical\ndevelopment, and institutional participation.\n\n\"CBIH is building its strategy around science, intellectual property,\nformulations, and regulatory discipline,\" said Dante Picazo, Chief Executive\nOfficer of Cannabis Bioscience International Holdings, Inc. \"While much of the\ncannabis sector has been driven by market cycles and short-term expectations,\nour firm is focused on creating a research-driven biotechnology platform in\ncomplex disease areas where inflammation, oxidative stress, immune response,\nmitochondrial function, and gene-expression regulation may overlap. We believe\nthis approach can support future opportunities for licensing, clinical\ncollaboration, manufacturing relationships, strategic partnerships, and\nlong-term shareholder value.\"\n\nEpigenetic regulation refers to biological mechanisms that may influence how\ncells respond to stress without changing the DNA sequence itself. In melanoma\nresearch, these mechanisms may be relevant to tumor behavior, immune response,\ndisease progression, and aging-related cellular stress. \"Our melanoma-related\nprogram reflects CBIH's interest in the relationship between the\nEndocannabinoid System, epigenetic regulation, and complex oncology-related\ndisease mechanisms,\" said Jennifer Salguero, Biologist, PhD in Science,\nUniversity of São Paulo, Brazil, and Chief Patent Officer of CBIH. \"This work\nsupports our broader commitment to disciplined cannabinoid research, patent\ndevelopment, and formulation science.\"\n\nThis initiative forms part of CBIH's portfolio of 25 finalized patent\napplications, including 10 applications already submitted to the USPTO and 15\nadditional applications finalized and ready for submission. The portfolio\ncovers neurological, autoimmune, oncological, metabolic, and other complex\ndisease areas, within a broader body of more than 100 medical formulation\nintellectual property assets.\n\nAs cannabinoid-based medicine continues to evolve, CBIH believes that\nscientific credibility, intellectual property protection, and responsible\nregulatory execution will be essential to building lasting value. The Company\nintends to continue advancing a sustainable competitive advantage from its\nposition as a serious participant in the emerging cannabinoid biotechnology\nsector.\n\nFORWARD-LOOKING STATEMENTS\n\nThis press release may contain forward-looking statements. The words\n\"believe,\" \"expect,\" \"should,\" \"intend,\" \"estimate,\" \"projects,\" variations of\nsuch words and similar expressions identify forward-looking statements, but\ntheir absence does not mean that a statement is not a forward-looking\nstatement. These forward-looking statements are based upon the Company's\ncurrent expectations and are subject to a number of risks, uncertainties, and\nassumptions. The Company undertakes no obligation to update any\nforward-looking statements, whether as a result of new information, future\nevents, or otherwise. Among the important factors that could cause actual\nresults to differ significantly from those expressed or implied by such\nforward-looking statements are risks that are detailed in the Company's\nfilings, which are on file at www.OTCmarkets.com.\n\nFor more information, contact us at:\n\n(214) 733-0868\nir@cbih.net\nDante Picazo\nCEO - CBIH\nWebsite: www.cbih.net\nX: https://x.com/CBIHMD\nInstagram: www.instagram.com/CBIHSTOCK\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/299514"},"type":"article","timestamp":"2026-06-01T11:00:15.064676832Z","server_sent_at_ms":1780311615064},"received_at":"2026-06-01T11:00:15.131Z","source_url":"https://www.newsfilecorp.com/release/299514"},"analysis":{"id":"40049","press_release_id":"50617","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Pre-revenue company with no disclosed clinical trial data or revenue streams","Heavy reliance on forward-looking statements regarding future licensing and partnerships"],"eventType":"operations_update","narrative":"Cannabis Bioscience International Holdings (CBIH) announced the completion of a patent-ready melanoma research program focused on cannabinoid science and epigenetic regulation.\n\nThe initiative adds to the company's portfolio of 25 finalized patent applications, with 10 already submitted to the USPTO and 15 ready for submission.\n\nManagement highlighted the upcoming DEA administrative hearing on marijuana rescheduling as a potential tailwind for the broader cannabinoid research environment.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine IP milestone for micro-cap cannabinoid biotech; low signal for active trading."},"keyFigures":{"customDimensions":{"total_ip_assets":100,"uspto_submitted":10,"ready_for_submission":15,"total_patent_applications":25}},"quotedText":"CBIH is building its strategy around science, intellectual property, formulations, and regulatory discipline","namedEntities":{"people":[{"name":"Dante Picazo","role":"CEO"},{"name":"Jennifer Salguero","role":"Chief Patent Officer"}],"products":[],"companies":[{"name":"Cannabis Bioscience International Holdings, Inc.","ticker":"CBIH"},{"name":"DEA","relationship":"regulator"},{"name":"USPTO","relationship":"regulator"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Completion of a patent application program is a routine R&D milestone for a pre-revenue biotech. It signals intellectual property accumulation but does not represent a binary regulatory event, revenue generation, or immediate commercialization. The mention of the upcoming DEA hearing is external macro context, not a direct benefit to the filer."},"tickerRelevance":{"others":[],"primary":"CBIH"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"rd_milestone","sectorWeight":"niche_biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Cannabis Bioscience International Holdings (CBIH) announced the completion of a patent-ready melanoma research program focused on cannabinoid science and epigenetic regulation.\n\nThe initiative adds to the company's portfolio of 25 finalized patent applications, with 10 already submitted to the USPTO and 15 ready for submission.\n\nManagement highlighted the upcoming DEA administrative hearing on marijuana rescheduling as a potential tailwind for the broader cannabinoid research environment.","key_figures":{"customDimensions":{"total_ip_assets":100,"uspto_submitted":10,"ready_for_submission":15,"total_patent_applications":25}},"named_entities":{"people":[{"name":"Dante Picazo","role":"CEO"},{"name":"Jennifer Salguero","role":"Chief Patent Officer"}],"products":[],"companies":[{"name":"Cannabis Bioscience International Holdings, Inc.","ticker":"CBIH"},{"name":"DEA","relationship":"regulator"},{"name":"USPTO","relationship":"regulator"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-01T11:13:59.199Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"rd_milestone","sectorWeight":"niche_biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"durationMs":30544,"modelName":"george-droid-qwen-72b"}}